Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 5/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | MELK | Q14680 | 2/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 3/20 | 0.38 |
| ▸ | ACACA | Q13085 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069637 | 0.84 | SIRT2 (0.47) | SUV39H2SIRT2SIRT1SIRT3CKS1B | |
| SCHEMBL4069719 | 0.83 | SUV39H2 (0.48) | SUV39H2SIRT2SIRT1SIRT3MELK | |
| SCHEMBL5751891 | 0.80 | ENPP1 (0.42) | SUV39H2MELKKCNH2DYRK1A | |
| SCHEMBL14169770 | 0.77 | DRD2 (0.52) | SUV39H2DRD2 | |
| SCHEMBL4073225 | 0.77 | SUV39H2 (0.47) | SUV39H2SIRT2SIRT1SIRT3CKS1B | |
| SCHEMBL13238463 | 0.77 | DRD2 (0.52) | SUV39H2KCNH2DRD2 | |
| SCHEMBL17861460 | 0.75 | CKS1B (0.48) | SUV39H2CKS1BSKP1SKP2KCNH2 | |
| SCHEMBL4074224 | 0.74 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL1222880 | 0.74 | CYP8B1 (0.48) | SUV39H2CKS1BSKP1SKP2ACACB | |
| SCHEMBL4068344 | 0.74 | KCNH2 (0.42) | KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605938-B1 | Antibacterial derivatives of napthydrin and quinoline | GLAXO GROUP LTD (GB) | 2009-02-11 | — | — | EP | disclosed |
| EP-1605938-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20060189601-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
| EP-1605938-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004087145-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189601-A1 | Antibacterial agents | NQO2, NRDC, IFNG | SUV39H2 3278/4885SIRT2 733/4885SIRT1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.